TY - JOUR
T1 - All Children Deserve to Be Safe, Mothers Too
T2 - Evidence and Rationale Supporting Continuous Glucose Monitoring Use in Gestational Diabetes Within the Medicaid Population
AU - Levy, Carol J.
AU - Galindo, Rodolfo J.
AU - Parkin, Christopher G.
AU - Gillis, Jacob
AU - Argento, Nicholas B.
N1 - Publisher Copyright:
© 2023 Diabetes Technology Society.
PY - 2024/9
Y1 - 2024/9
N2 - Gestational diabetes mellitus (GDM) is a common metabolic disease of pregnancy that threatens the health of several million women and their offspring. The highest prevalence of GDM is seen in women of low socioeconomic status. Women with GDM are at increased risk of adverse maternal outcomes, including increased rates of Cesarean section delivery, preeclampsia, perineal tears, and postpartum hemorrhage. However, of even greater concern is the increased risk to the fetus and long-term health of the child due to elevated glycemia during pregnancy. Although the use of continuous glucose monitoring (CGM) has been shown to reduce the incidence of maternal and fetal complications in pregnant women with type 1 diabetes and type 2 diabetes, most state Medicaid programs do not cover CGM for women with GDM. This article reviews current statistics relevant to the incidence and costs of GDM among Medicaid beneficiaries, summarizes key findings from pregnancy studies using CGM, and presents a rationale for expanding and standardizing CGM coverage for GDM within state Medicaid populations.
AB - Gestational diabetes mellitus (GDM) is a common metabolic disease of pregnancy that threatens the health of several million women and their offspring. The highest prevalence of GDM is seen in women of low socioeconomic status. Women with GDM are at increased risk of adverse maternal outcomes, including increased rates of Cesarean section delivery, preeclampsia, perineal tears, and postpartum hemorrhage. However, of even greater concern is the increased risk to the fetus and long-term health of the child due to elevated glycemia during pregnancy. Although the use of continuous glucose monitoring (CGM) has been shown to reduce the incidence of maternal and fetal complications in pregnant women with type 1 diabetes and type 2 diabetes, most state Medicaid programs do not cover CGM for women with GDM. This article reviews current statistics relevant to the incidence and costs of GDM among Medicaid beneficiaries, summarizes key findings from pregnancy studies using CGM, and presents a rationale for expanding and standardizing CGM coverage for GDM within state Medicaid populations.
KW - CGM
KW - Centers for Medicare & Medicaid Services
KW - GDM
KW - Medicaid
KW - continuous glucose monitoring
KW - gestational diabetes
KW - insurance coverage
KW - type 1 diabetes
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85150890558&partnerID=8YFLogxK
U2 - 10.1177/19322968231161317
DO - 10.1177/19322968231161317
M3 - Comment/debate
C2 - 36919680
AN - SCOPUS:85150890558
SN - 1932-2968
VL - 18
SP - 1198
EP - 1207
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
IS - 5
ER -